Cellectar shares surge 12.05% intraday following FDA Rare Pediatric Disease designation for iopofosine I-131 and positive clinical data from CLOVER-2 trial.

Cellectar surged 12.05% intraday following a regulatory milestone and positive clinical data. The U.S. FDA granted iopofosine I-131 the Rare Pediatric Disease Designation for treating inoperable, recurrent, or refractory pediatric high-grade glioma, underscoring its potential in an underserved oncology niche. Interim Phase 1b CLOVER-2 trial results showed progression-free survival of 5.4 months and overall survival of 8.6 months in patients receiving a minimum dose of 55 mCi, reinforcing therapeutic promise. Additionally, preclinical data for CLR 121225, an actinium-based radiopharmaceutical, demonstrated significant tumor growth inhibition in pancreatic cancer models, signaling pipeline expansion beyond iopofosine. These developments, coupled with the stock’s recent 5.86% rise on Tuesday, reflect investor optimism about Cellectar’s clinical progress and its positioning in the radiopharmaceuticals market.